tbuckley/cabot-search huggingface dataset:
Hibernoma
Authors: Barry E Chatterton, Dominic Mensforth, Brendon J Coventry, Penelope Cohen
Journal: Clinical Nuclear Medicine (2002)

CHATTERTON, BARRY E. M.B.B.S., F.R.A.C.P.*; MENSFORTH, DOMINIC Dip.Ap.Sci.†; COVENTRY, BRENDON J. M.B.B.S., F.R.A.C.S., Ph.D.‡; COHEN, PENELOPE M.B.Ch.B., F.R.C.P.(A)§ Author Information
Elevated Expression of the C-fes Proto-oncogene in Adult Human Myeloid Leukemia Cells in the Absence of Gene Amplification
Authors: T. E. Smithgall, J. B. Johnston, M. Bustin, R. I. Glazer
Journal: JNCI Journal of the National Cancer Institute (1991)

Expression of the 93-kd tyrosine kinase encoded by the human c-fes proto-oncogene(also known as FES) is restricted to mature hematopoietic cells of the granulocytic and monocytic lineages, suggestive of a function essential to normal myeloid differentiation. However, recent studies have shown that c-fes can transform fibroblasts if sufficient levels of gene expression are achieved. These findings indicate that strict regulation of the c-fes gene is critical to normal myeloid development, whereas elevated c-fes expression may contribute to malignant transformation. In the present study, we compared the c-fes messenger RNA (mRNA) levels in leukemia blasts from patients with myeloid of lymphoid leukemia with those of peripheral monocytes from a normal donor with the use of a quantitative ribonuclease protection assay. The presence of c-fes mRNA was readily detected in both acute myeloid leukemia(AML) and chronic myeloid leukemia (CML) cells, but c-fes mRNA was present in low levels or was absent in lymphoid leukemia cells. The leukemia cells of two of five AML patients and four of four CML patients expressed more c-fes mRNA than monocytes from a normal donor, with more than a threefold elevation in the cells of one CML patient. No evidence of amplification of rearrangement of the c-fes gene was detectable by Southern blot analysis of myeloid leukemia DNA, suggesting that the variation in c-fes mRNA levels are related to differences in transcriptional activity and/or message stability. These results indicate that elevated c-fes expression is a common feature of myeloid leukemia cells that could potentially contribute to the leukemia phenotype. [J Nati Cancer Inst 83: 42–46, 1991]
Abstract LB-381: Inhibition of the hedgehog signaling pathway has significant preclinical activity and prevents development of androgen-independent prostate cancer
Authors: Devalingam Mahalingam, Sitai Liang, Silvia Buonamici, LuZhe Sun
Journal: Cancer Research (2011)

Abstract Introduction: Prostate cancer (PCa) is the second leading cause of cancer death in American men. Patients with advance PCa are often treated first with anti-androgen therapy, but will invariably develop androgen-independent prostate cancer (AIPC). A recent study has shown that androgen deprivation can lead to increased expression of hedgehog signaling components. Hedgehog signaling is also known for normal and cancer stem cell self-renewal. Therefore, in this study, we tested the hypothesis that the inhibition of hedgehog pathway with a novel hedgehog inhibitor, LDE225 (Novartis®), will block the development and growth of AIPC. Methods and Results: Two androgen-dependent PCa (ADPC) cell lines were adapted to grow in an androgen-free culture medium. The emergence of AIPC cells was found to be associated with increased expression of hedgehog ligands, and hedgehog signaling activity through the activation of its downstream Gli transcription factors as detected using a Gli-responsive promoter luciferase reporter. We also found that treatment with LDE225 was more effective in inhibiting the growth of AIPC cells than ADPC cells. Furthermore, the treatment with LDE225 also inhibited the emergence of AIPC cells when the ADPC cells were cultured in the androgen-free medium. Finally, treatment of orthotopic xenograft PCa model with LDE225 is underway to confirm our pre-clinical in-vitro activity in both ADPC and AIPC models. Conclusion: These results support our hypothesis that the activation of hedgehog pathway contributes to the development of AIPC and provide the rationale and guidance for design of clinical trials utilizing LDE225 in PCa patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-381. doi:10.1158/1538-7445.AM2011-LB-381
A7.03 Il-33 inhibits experimental arthritis through CD25<sup>+</sup>and CD25<sup>-</sup>regulatory T cells activation
Authors: J Biton, F Santinon, D Lemeiter, MC Boissier, N Bessis
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Interleukin (IL)-33 is a new member of the IL-1 family that exerts pleiotropic activities in innate and &nbsp;adaptive immunity. Some evidence also suggest that the IL-33/ST2 (IL-33 receptor) axis is strongly involved in the pathophysiology of rheumatoid arthritis (RA). We recently showed that IL-33 was able to inhibit collagen-induced arthritis (CIA) by promoting a regulatory T cell (Tregs) population overexpressing CD39 and ST2L. This work aimed at further enlightening the involvement of regulatory T cells in the IL-33-mediated effect in arthritis. <h3>Results</h3> To further study the implication of Treg in IL-33 therapeutic effect, we evaluated IL-33 mediated effect in the absence of CD25<sup>+</sup> Treg in CIA by co-administering IL-33 together with a depleting anti-CD25 antibody. As expected, this antibody obviously suppressed CD25 expressing CD4<sup>+</sup>FoxP3<sup>+</sup> Treg population. In contrast, while CD4<sup>+</sup>FoxP3<sup>+</sup>CD25<sup>+</sup> Treg were depleted, IL-33 dramatically amplified a population of CD25 negative CD4<sup>+</sup>FoxP3<sup>+ </sup>Treg in mice with CIA. We confirmed in an<i> in vitro</i> system this strong impact of IL-33 on CD25<sup>-</sup> Treg. On the contrary, IL-2 had no impact <i>in vitro</i> on this non-expressing CD25 cells. <h3>Conclusion</h3> In absence of the alpha chain of the IL-2 receptor (CD25), IL-33 is still able to induce Treg expansion probably independently of IL-2 by a direct effect on ST2L-expressing Treg. Finally, this set of experiments reinforces the strong impact of IL-33 on both CD25<sup>+</sup> and CD25<sup>-</sup> Treg subpopulations, therefore strengthening the involvement of these cells in the therapeutic effect of IL-33 in CIA.
Low-Tar Cigarettes Pose Hidden Health Threat, Panel Says
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Low-Tar Cigarettes Pose Hidden Health Threat, Panel Says Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 1, 4 January 1995, Pages 15–16, https://doi.org/10.1093/jnci/87.1.15 Published: 04 January 1995
"AM STEINHOF"
Authors: L. Vernon Briggs
Journal: American Journal of Psychiatry (1909)

A few miles outside the City of Vienna, on high land overlooking the city on the one side and surrounded on two sides by most When the Main General Hospital was built in Vienna, Emperor Joseph II decreed that there should be erected one building exclusively for the mental patients.This circular insane tower, built about 1760, which is now used for storerooms and nurses' quarters, is situated at the rear of the General Hospital, was alone used for insane patients until 1803, when the so-called Lazarettes was added for quiet curable patients and also the great almshouse for quiet incurables.These institutions were maintained from funds partly reaching back to the time of the Crusades and partly from
FRI0380 Efficacy and Safety of Leflunomide Therapy in Lupus Nephritis:A Meta-Analysis
Authors: H. Zeng, Q. Ren
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To evaluate the efficacy and safety of leflunomide in treating lupus nephritis (LN). <h3>Methods</h3> According to the requirements of meta-analysis, a literature search about efficacy and safety of leflunomide therapy in LN was performed among Cochrane clinical controlled trials database, PubMed, BMJ-Clinical Evidence, CNKI, VIP and Wanfang data from the establishment of the database till December 2010.All included RCTs were graded in term of randomization, allocation concealment and blinding and non-RCTs were graded in term of grouping method, blinding, withdrawal and loss of follow-up, baseline comparability, diagnostic criteria and bias control. RevMan 5.0 software was used for meta-analysis. <h3>Results</h3> A total of 828 literatures were included. Five RCTs and 2 non-RCTs were enrolled for meta-analysis. Four RCTs described the method of random allocation, 1 literature used double blind method. Five RCTs were all lack of information about allocation concealment, selectively reporting and other bias, but reported withdrawal and loss of subjects. Two non-RCTs were lack of grouping method and blinding, but reported withdrawal and loss of subjects, also used established diagnostic criteria. Leflunomide group was treated with leflunomide and glucocorticoid, while control group was given cyclophosphamide and glucocorticoid or placebo. 1. There was no significant difference in complete remission rate (OR=1.51, 95%CI: 0.90-2.54), partial remission rate (OR=1.06, 95%CI: 0.70-1.61) or overall remission (OR=1.63, 95%CI: 0.98-2.71) between leflunomide group and cyclophosphamide group. 2. The 24 h urine protein, SCr and SLEDAI scores of leflunomide group were significantly lower than that of cyclophosphamide group. There was no significant difference in C3,positive rate of anti-ds DNA between leflunomide group and cyclophosphamide group. 3. There was no significant difference in infection, herpes zoster,hypertension, palpitations, leukopenia, alopecial, elevation in ALT, memoxenia, rashes, or the incidence of gastrointestinal reactions between the two groups. <h3>Conclusions</h3> Based on the current evidence, the efficacy and safety of leflunomide for treatment of LN are close to cyclophosphamide. Further evidence from RCT studies is needed to elucidate the efficacy and safety of leflunomide for LN. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5566
AB0705 EULAR sjÖgren’s syndrome disease activity index (ESSDAI) is sensitive to show treatment efficacy of rituximab in patients with primary sjÖgren’s syndrome
Authors: R.V. Moerman, S. Arends, P.M. Meiners, J.M. Meijer, F.G. Kroese, A. Vissink, H. Bootsma
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Recently, the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) has been developed to measure clinical disease activity in patients with Sjögren’s syndrome.(1) In an open label trial with rituximab (RTX) we showed that the ESSDAI is sensitive to measure treatment efficacy in patients with primary Sjögren’s syndrome (pSS),(2) but data from a randomized controlled trials are not yet available. <h3>Objectives</h3> To evaluate the responsiveness of the ESSDAI in pSS patients treated with RTX or placebo. <h3>Methods</h3> In a randomized controlled trial, thirty patients with pSS, as determined by the revised American-European Consensus Group criteria, were treated with either RTX (1000 mg; n=20) or placebo infusions (n=10) on days 1 and 15. Follow-up was conducted at 5, 12, 24, 36 and 48 weeks after treatment. During all scheduled follow-up visits the ESSDAI was scored using the patient’s charts by an independent observer blinded for the treatment. The ESSDAI scores over time were analyzed with generalized estimating equations. Responsiveness of ESSDAI was assessed using standardized response mean (SRM) and effect size (ES). SRM and ES &lt;0.5 were interpreted as small, between 0.5 and 0.8 as moderate and &gt;0.8 as large. <h3>Results</h3> The median (range) ESSDAI scores at baseline were 8.0 (4-13) and 6.5 (2-13) in the RTX and placebo groups, respectively. In the RTX group, the ESSDAI scores decreased significantly at week 5 to 36 after treatment and returned to baseline values at week 48. In the placebo group, the ESSDAI scores decreased significantly only at week 5, probably due to the use of corticosteroids to prevent side effects (125 mg i.v. given just before the RTX infusions, and 5 days oral prednisone (2 days 60 mg, 2 days 30 mg and 1 day 15 mg)) and were comparable to baseline values for all other time points (Figure 1). The ES and SRM for the ESSDAI in RTX group were large at weeks 5, 12, and 24, moderate at week 36 and small at week 48. In the placebo group, ES and SRM were moderate at week 5 and small at all other time points. <h3>Conclusions</h3> The ESSDAI is a sensitive tool to measure disease activity changes in patients with pSS after RTX treatment. The present results support the use of the ESSDAI in future clinical trials. <h3>References</h3> Seror R, Ravaud P, Bowman S, et al. EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjögren’s syndrome. Ann Rheum Dis 2010;69:1103-9. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis. 2011; 2012 Jan 17. [Epub ahead of print]. <h3>Disclosure of Interest</h3> None Declared
SAT0236 Prevalence of Syndesmophytes in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis (AXSPA) Not Fulfilling the Modified New York (MNY) Criteria
Authors: M. De Hooge, D. Van Den Berg, F. van Gaalen, M. Reijnierse, M. V. Navarro Compán, K. M. Fagerli, M. Turina, M. van Oosterhout, L. Punzi, T. Huizinga, D. Van Der Heijde
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The mNY criteria<sup>1</sup>, which indicate sacroiliitis of at least grade 2 bilaterally or grade 3 or 4 unilaterally, are used to classify patients (pts) as Ankylosing Spondylitis (AS). However, little is known about the occurrence of syndesmophytes in the spine in the absence of radiographic sacroiliitis. <h3>Objectives</h3> To investigate if syndesmophytes are prevalent in pts with chronic back pain suspected of axSpA who are not fulfilling the mNY criteria and if syndesmophytes should be included to define pts as having radiographic axSpA. <h3>Methods</h3> Pts with back pain (≥3 months, ≤2 years, onset ≤45 years) recruited from 5 participating centres across Europe were included in the SPondyloArthritis Caught Early (SPACE)-cohort. All patients underwent conventional radiographs of the cervical and lumbar spine and sacroiliac (SI)-joints (X-spine and X-SI, respectively). X-spine was scored on the presence or absence of ≥1 syndesmophyte, X-SI was scored according to the mNY<sup>1</sup>. X-rays were scored independently by 3 readers. Lesions were considered present if 2/3 readers agreed. <h3>Results</h3> All pts with both X-spine and X-SI data available (n=302) were used for comparison. There were 26 pts (8.6%) fulfilling the mNY criteria and 7 pts (2.3%) with ≥1 syndesmophyte present in the spine. None of those 7 pts showed radiographic sacroiliitis nor active lesions on MRI of the SI joints. Two pts fulfil the ASAS axSpA criteria and 5 had SpA features but did not fulfil the criteria. In table 1 the number and location of syndesmophytes and SpA features are presented. Most pts (n=5) had 1 syndesmophyte. The two pts with &gt;1 syndesmophyte did not fulfil the ASAS axSpA criteria. All pts had syndesmophytes located solely in the cervical part of the spine. Only 2/302 (0.7%) pts would be considered as having signs of radiographic axSpA if syndesmophytes (in absence of radiographic sacroiliitis) would be considered a sign of radiographic involvement. <h3>Conclusions</h3> In this population, syndesmophytes in pts without sacroiliitis on radiographs and MRI are infrequent and solely located in the cervical spine. Indicating that syndesmophytes are not informative in classifying pts as having radiographic axSpA in early disiease. <h3>References</h3> van der Linden S A&amp;R 984;27:361–8 <h3>Disclosure of Interest</h3> None Declared
P17.95 * NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA
Authors: E. T. Wong, H. H. Engelhard, D. D. Tran, Y. Kew, M. M. Mrugala, R. Cavaliere, J. L. Villano, J. Rudnick, A. L. Sumrall, J. Zhu
Journal: Neuro-Oncology (2014)

BACKGROUND: The NovoTTF-100A is a first-of-a-kind anticancer device, approved by the Food and Drug Administration in 2011, for the treatment of recurrent glioblastomas. It emits alternating electric fields, at an intensity of 1 V/cm and a frequency of 200 kHz, that mimic the cytotoxic effect of chemotherapy by disrupting charged cytoplasmic proteins involved in the tightly orchestrated process of mitosis. Past phase III trial demonstrated equivalent efficacy when the device was compared to conventional cytotoxic chemotherapies and bevacizumab, but without their systemic side effects. METHODS: The NovoTTF-100A device has been available by prescription at 91 oncology centers in the United States since November 2011. We retrospectively analyzed the outcome and toxicity data from patients who were prescribed the device from October 2011 to November 2013 as treatment for their recurrent glioblastomas. RESULTS: There were 147 female and 310 male patients (n = 457) who were treated with this device. The median age was 55 (range 18 to 86) years. The Kaplan-Meier median OS was 9.6 (95% confidence interval [CI] 8.0 to 13.7) months and the median treatment duration was 4.1 (95% CI 3.5 to 4.8) months. The most common device-related adverse events include skin reaction (24.3%), neurological disorders(10.4%), heat sensation (8.9%), electric sensation (7.7%) and headache (5.7%). CONCLUSIONS:Treatment with NovoTTF-100A, as prescribed in the general clinical setting to patients with recurrent glioblastomas, offers favorable outcomes compared to historical patient data. The adverse event profile of the device remains benign with no new unexpected toxicities.
Formaldehyde Exposure and Nasopharyngeal Cancer: Re-examination of the National Cancer Institute Study and an Update of One Plant
Authors: J. J. COLLINS, J. C. CAPOROSSI, H. MICHAEL, D. UTIDJLAN
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Formaldehyde Exposure and Nasopharyngeal Cancer: Re-examination of the National Cancer Institute Study and an Update of One Plant Get access JAMES J. COLLINS, JAMES J. COLLINS American Cyanamid Company One Cyanamid PlazaWayne, NJ 07470 Search for other works by this author on: Oxford Academic PubMed Google Scholar JOSEPH C. CAPOROSSI, JOSEPH C. CAPOROSSI American Cyanamid Company One Cyanamid PlazaWayne, NJ 07470 Search for other works by this author on: Oxford Academic PubMed Google Scholar H. MICHAEL, H. MICHAEL American Cyanamid Company One Cyanamid PlazaWayne, NJ 07470 Search for other works by this author on: Oxford Academic PubMed Google Scholar D. UTIDJLAN D. UTIDJLAN American Cyanamid Company One Cyanamid PlazaWayne, NJ 07470 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 5, 4 May 1988, Pages 376–377, https://doi.org/10.1093/jnci/80.5.376 Published: 04 May 1988
Bladder Herniation Within the Inguinal Canal Simulating Paget’s Disease
Authors: STEVEN M. SORENSON, AMILCARE GENTILI
Journal: Clinical Nuclear Medicine (2001)

From the West Los Angeles VA Medical Center and UCLA School of Medicine, Los Angeles, California Received for publication January 3, 2001. Accepted February 19, 2001. Reprint requests: Steven M. Sorenson, 10833 Le Conte Avenue, Department of Radiology, UCLA School of Medicine, Los Angeles, California 90095. E-mail: [email protected]
Autonomic Regulation of Lymphatic Flow in the Lower Extremity Demonstrated on Lymphoscintigraphy in Patients With Reflex Sympathetic Dystrophy
Authors: DOUGLAS HOWARTH, RICHARD BURSTAL, CHRIS HAYES, LINDA LAN, GENA LANTRY
Journal: Clinical Nuclear Medicine (1999)

Purpose: Nuclear medicine techniques were used to show that the peripheral lymphatics are under autonomic control in much the same way as the blood vessels that supply the same anatomic region. Methods: Three patients with complex regional pain syndrome type 1 (reflex sympathetic dystrophy) involving a lower extremity were evaluated using three-phase bone scintigraphy and peripheral lymphoscintigraphy. Each patient was treated with ipsilateral chemical lumbar sympathectomy, and lymphoscintigraphy was repeated within several days of the procedure. Results: All three patients had evidence of decreased flow (compared with the contralateral extremity) to normal flow after ipsilateral sympathectomy. Bone scintigraphy, before and after sympathectomy, was difficult to interpret because of the effects of altered weight bearing. Two patients who had unilateral peripheral edema showed marked improvement after sympathectomy and increased lymphatic flow. Conclusions: Peripheral lymphatic function is controlled by the autonomic nervous system. In reflex sympathetic dystrophy, peripheral edema may be caused by an increased sympathetic stimulus to the lymphatics. Further study of this phenomenon may show that nuclear medicine studies, such as bone scintigraphy and lymphoscintigraphy, can be used to distinguish patients who will benefit from sympathectomy from those who will not, thereby obviating invasive testing and unnecessary invasive treatment.
EVOLUTION OF THE GLIOBLASTOMA GENOME IN RESPONSE TO TREATMENTS
Authors: D.-H. Nam, J. Kim, H. J. Cho, I.-H. Lee, D.-S. Kong, H. J. Seol, J.-I. Lee, W.-Y. Park
Journal: Neuro-Oncology (2014)

BACKGROUND: Glioblastoma multiforme (GBM), the most common and aggressive malignant brain tumor, almost always recurs despite aggressive treatments combining surgery, radiation, and chemotherapy. Thus, understanding how individual tumors evolve in response to the standard treatments is essential for improved patient care. METHODS: Here, we describe our genomic analysis of the paired pre- and post-treatment tumors from 20 glioblastoma patients. RESULTS: Tumors also acquired diverse alterations that appeared to contribute to treatment resistance, such as the increased expression of CDK4/6 in the IDH1-mutated tumors and novel EGFR and MET mutations, in addition to TP53, RB1, and APC alterations that were previously implicated with treatment resistance. CONCLUSIONS: The patient-specific genomic alterations that arise following treatments may represent superior therapeutic targets for recurrent GBMs. This work suggests that assessing genomic changes in individual tumors after recurrence is paramount for precision neuro-oncology. SECONDARY CATEGORY: Tumor Biology.